Aerosol pirfenidone and pyridone analog compounds and uses thereof
Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
1. An aqueous solution of pirfenidone for The treatment of interstitial lung disease in a subject, wherein the treatment comprises nebulized administration from a nebulizer by inhalation to the subject, the aqueous solution comprising:
water, pirfenidone at a concentration from about 3.0 mg/ml to about 16.0 mg/ml;
a citrate buffer formulated with sodium citrate:
sodium chloride at a concentration between 100 mM and 200 mM; and
a taste masking agent that is sodium saccharin, present at a concentration between 0.1 mM and 0.9 mM;
wherein the concentration of sodium saccharin is from between 0.1 mM and 0.4 mM at pirfenidone concentrations of about 3.0 mg/ml to a concentration of sodium saccharin is between 0.5 mM and 0.9 mM at pirfenidone concentrations of about 16.0 mg/ml;
wherein the osmolality of the aqueous solution is from about 250 mOsmol/kg to about 500 mOsmol/kg,
wherein the pH of the solution is about 5.0 to about 6.0, and
wherein said treatment delivers a respirable delivered dose of between 4.2 and 15.5 Mg per 2.0 ml of fill volume of the aqueous solution in the nebulizer.
2. The aqueous solution according to claim 1 , wherein the nebulized administration delivers pirfenidone at a total pirfenidone output rate of between 0.1 mL/min and 1.0 mL/min, or less than or equal to 0.5 ml/min, or less than 0.7 ml/min.
3. The aqueous solution according to claim 1 , wherein: the sodium chloride concentration is about 150 mM.
4. The aqueous solution according to claim 1 , wherein the citrate buffer has a concentration of up to about 60 mM.
5. The aqueous solution of claim 4 , wherein the citrate buffer has a concentration of about 5 mil.
6. The aqueous solution of claim 1 , wherein the pH is about 5.5.
7. The aqueous solation of claim 1 , wherein the aqueous solution is a unit dose and wherein the nebulizer is a vibrating mesh nebulizer.
8. The aqueous solution according to claim 7 , wherein the liquid nebulizer: (i) after administration of the inhaled dose, achieves lung deposition of at least 7% of
the pirfenidone administered to the mammal; (ii) provides a Geometric Standard Deviation (GSD) of emitted droplet size distribution of the aqueous solution of about 1.0 μm to about 2.5 μm; (iii) provides droplets of the aqueous solution emitted with the high efficiency liquid nebulizer having: a) a mass median aerodynamic diameter (MMAD) of about 1 μm to about 5 μm; and/or b) a volumetric mean diameter (VIVID) of about 1 μm to about 5 μm; (iv) provides a fine particle fraction (FPF″% 5 μm) of droplets emitted from the liquid nebulizer of at least about 30%; (v) provides an output rate of at least 0.1 mL/min; and/or (vi) provides at least about 25% of the aqueous solution to a mammal.